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Background. The use of aldosterone antagonists has impor-
tant beneficial effects on the progression of renal and cardiac
disease reflected in a decrease of cardiovascular mortality and
renal failure. Nevertheless, the incidence of heart and end-
stage renal failure continues to increase. This leads to the
conclusion that mechanisms independent of the classical aldo-
sterone/mineralocorticoid receptor system may contribute to
the pathogenesis of cardiac and renal disease.
Methods. The mRNA expression profile of human renal epi-
thelial cells in response to aldosterone was characterized using
cDNA arrays covering 1430 genes. Differentially expressed
genes were further evaluated by quantitative reverse transcrip-
tion-polymerase chain reaction (RT-PCR), Northern blotting,
and estimating the gene products by Western blotting.
Results. Aldosterone treatment of cells resulted in signifi-
cant up-regulation of several genes within 1 hour, with sgk,
p21/waf1, gadd45, and gadd153 being the most significant ones.
Long-term treatment (4 hours) with aldosterone induced the
mRNA expression of ppara and pura. The mineralocorticoid
receptor inhibitor spironolactone decreased the mRNA levels
of sgk, p21/waf1, and gadd45, whereas the glucocorticoid recep-
tor inhibitor RU 486 reduced the mRNA level of sgk and p21/
waf1. Gadd153 was not affected by any of the inhibitors, proba-
bly indicating regulation by nonclassic mechanisms.
Conclusion. Among the early genes investigated in this
study, one transcript has been identified that is not suppressed
by antagonists of either glucocorticoid or mineralocorticoid
receptor. Further studies should be able to identify other genes
regulated in a similar manner that could explain the inefficacy
of spironolactone in some cases of aldosterone-mediated kid-
ney disease.
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Major physiologic activities of steroid hormones are
mediated by the family of steroid hormone receptors.
Such receptors act as ligand-inducible transcription fac-
tors by directly interacting as monomers, homodimers,
or heterodimers with the hormone-responsive elements
of target genes. These elements are located in regulatory
sequences, normally present in the 5 flanking region of
target genes. Steroid hormone receptors recognize and
bind to palindromic sequences, which are identical for
a wide variety of steroid hormone receptors such as glu-
cocorticoid receptor (GR), mineralocorticoid receptor
(MR), and androgen receptor (AR) [1]. In addition to
the classical mode of receptor action, which involves
binding to regulatory sequences in target gene promoters
and subsequent modulation of transcription, steroid hor-
mones might also act through alternative, nongenomic
pathways [2]. These actions are rapid, independent of
transcription and translation and mediated via receptors
that are not yet well understood. However, both nuclear
receptors [3] and nonclassic receptors [4] are believed
to act on gene expression also by mechanisms indepen-
dent of binding to a hormone-responsive element.
Classical steroid hormone receptors are closely re-
lated. Both GR and MR contain domains that are similar
in structure and function [5]. Although glucocorticoid
and mineralocorticoid hormones are able to bind to iso-
lated MR with the same affinity, several molecular mech-
anisms intervene to allow specific aldosterone responses
despite the large excess of plasma glucocorticoids. MR
is present in a wide variety of epithelial tissues such as
distal nephron, colon, salivary and sweat glands, but is
also established in other, nonepithelial tissues, including
the hippocampus, the cardiovascular system, and brown
adipose tissues. The primary action of aldosterone in
kidney epithelia is to regulate electrolyte and water ho-
meostasis [6], probably transmitted by phosphorylation
and/or an enhanced mRNA expression of epithelial so-
dium channel (ENaC) and Na,K-ATPase subunits.
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These actions are mediated via MR. However, the impact
of aldosterone on gene expression depends on target
tissues and varies among cell types [7].
On the other hand, aldosterone action may also detri-
mental under certain conditions, leading to hypertrophy,
remodeling and fibrosis in the kidney (for review, see
[8]) and the heart [9]. There is evidence that aldosterone
receptor antagonists, independent of the renin-angioten-
sin system, attenuate the occurrence of renal and cardiac
fibrosis in spontaneousely hypertensive stroke-prone
rats (SHRSP) [10]. The clinical relevance of this is under-
lined in the outcome of the Randomized Aldactone Eval-
uation Study (RALES) [11]. However, the precise mech-
anisms by which the aldosterone-MR system modulates
renal function are far from being well understood, and
there are reports on renal failure model systems where
spironolactone, the popular aldosterone antagonist, has
little effect [12]. This corresponds to clinical experience
and suggests the possibility of the existence of genes that
are modulated by aldosterone in a manner insensitive
to spironolactone, or possibly classic MR antagonists in
general. Further investigation of aldosterone-regulated
transcripts could elucidate additional pathways for renal
hypertrophy and remodeling, which may also serve as a
model for the study of similar processes in the heart.
Our rationale for this study was to search for genes that
are up-regulated rapidly by aldosterone and to test their
sensitivity toward inhibitors of the receptors that are
believed to mediate the responses.
METHODS
Cell culture
Human renal epithelial cells (HRE) and renal epithe-
lial growth medium (REGM) were purchased from Bio-
Whittaker, Apen, Germany. HRE are derived from whole
human kidney and contain renal proximal tubule epithe-
lial cells, distal tubule epithelial cells, and glomerular
epithelial cells. Cells were cultured according to the man-
ufacturer’s recommendations. After reaching confluency
(80%), cells were transferred to REGM without serum
and hydrocortisone. After 24 hours, 100 nmol/L aldoste-
rone or vehicle (0.01% ethanol) were added, and cells
further incubated for periods of 0.5 hour up to 24 hours.
Inhibitor studies
Stock solutions of spironolactone (Sigma, Taufkirchen,
Germany), cycloheximide (Sigma), actinomycin D (Serva,
Heidelberg, Germany), aldosterone (Fluka, Neu-Ulm,
Germany) and RU 486 (Roussel Uclaf, Roumainville,
France) were set up in ethanol. For inhibitor studies, cell
cultures were transferred to serum- and hydrocortisone-
free medium and subsequently exposed to various con-
centrations of inhibitors and/or aldosterone or vehicle.
Inhibitors were added 5 minutes before aldosterone at
the following concentrations: cycloheximide (5 g/mL),
actinomycin D (1 g/mL), spironolactone (100 mol/L),
and RU 486 (100 mol/L). After incubation for 1 hour,
cells were washed twice in phosphate-buffered saline
(PBS) buffer and stored at 80C until RNA isolation.
RNA isolation
Total RNA was isolated using Trizol reagent (Life
Technologies, Karlsruhe, Germany) according to the man-
ufacturer’s instructions. Yield and purity of total RNA
were estimated by optical density at 260 nm/280 nm. All
RNA preparations contained intact RNA with distinct
28S, 18S, and 5S bands. PolyA RNA was isolated from
1 mg total RNA using oligotex particles (Qiagen, Hilden,
Germany). For array hybridization, Northern blotting,
and reverse transcription-polymerase chain reaction (RT-
PCR), RNA isolation was performed in three indepen-
dent experiments.
Northern blot analysis
Northern blot analysis was carried out under standard
conditions. Briefly, 20g total RNA for sgk and p21/waf1
or 1 g polyA RNA (all other genes) from aldosterone-
treated or control cells were separated on a 0.9% dena-
turing agarose gel containing 0.67% formaldehyde. RNA
was then transferred by capillary action to Hybond N
membranes (Amersham Pharmacia Biotech, Freiburg,
Germany) and immobilized by baking at 80C for 2
hours. For probe generation, 50 ng purified PCR product
(RT-PCR primers) was labeled with -32P deoxycytidim-
ine triphosphate (dCTP) (6000 Ci/mmol) (Amersham
Pharmacia Biotech) to a specific activity of 1.5  109
cpm/g using Ready-to-Go labeling beads (Amersham
Pharmacia Biotech) following the manufacturer’s recom-
mendations. Unincorporated nucleotides were removed
using Chroma-Spin 30 diethyl pyrocarbonate (DEPC) col-
umns (Clontech Laboratories, Heidelberg, Germany).
Prehybridization and hybridization were performed in
ExpressHyb hybridization solution (Clontech Labora-
tories), supplemented with 50 g/mL denatured salmon
sperm DNA (Life Technologies) at 68C for 1 hour and
16 hours, respectively. Membranes were washed twice
with 2  standard sodium citrate (SSC), 1% sodium
dodecyl sulfate (SDS) for 30 minutes at 68C. Final wash
was done in 0.5 SSC, 0.5% SDS for 15 minutes at 60C.
Radioactive signals were quantified by phosphorimaging
using the Bio-Image Analyzer BAS 2500 (Fuji, Inc.,
Tokyo, Japan). Membranes were stripped by washing in
2  SSC, 0.1% SDS at 95C for 10 minutes, and then
rehybridized with a cDNA probe of glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH). Results are ex-
pressed relative to GAPDH.
cDNA array hybridization
Differential gene expression was investigated by using
the Atlas Human cDNA Expression Array 1.2 III and
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the Atlas Human cDNA Stress Expression Array (Clon-
tech) according to the manufacturer’s protocol. In brief,
5 g DNase I–treated total RNA were reversely tran-
scribed with 1 L gene-specific primers and 5 L -32P
deoxyadenosine triphosphate (dATP) (3000 Ci/mmol)
(Amersham Pharmacia Biotech) using 200 U MMLV
Superscript II RT (Life Technologies). Radiolabeled
cDNA probes were purified using Chroma Spin-200
DEPC-H2O columns (Clontech Laboratories) and counted
in a Beckman LS 6500 liquid scintillation counter. For
array hybridization, equal amounts of radiolabeled cDNA
probes were used (typically 5.2  106 cpm per mem-
brane). Prehybridization and hybridization were per-
formed as described above for Northern blot analysis.
After a final wash (0.1  SSC, 0.5% SDS, 68C, 30 min-
utes), the membranes were exposed to a phosphorimaging
screen at room temperature for 5 days. Phosphorimages
were scanned using the Bio-Image Analyzer BAS 2500
and analyzed with the AtlasImage 1.5 Software (Clon-
tech Laboratories). The signal for a transcript was con-
sidered significantly elevated above background at an
adjusted intensity (total signal minus background) of
more than twice the background signal. Normalization
of the data was performed by dividing the intensity of
each transcript on a blot by the average intensity of all
of the genes on that blot.
Analysis of mRNA expression by RT-PCR
cDNA synthesis was performed from 5 g DNase
I–treated total RNA using Superscript II RT (Life Tech-
nologies) according to the manufacturer’s instructions.
The reaction was stopped by heat inactivation and then
DEPC-H2O was added to the samples up to 100L. PCR
amplification was performed using Advantage cDNA
polymerase mix (Clontech Laboratories) according to
the manufacturer’s recommendations in a total volume
of 50 L containing 2 L of the diluted cDNA, 1 mol/L
betaine (pH 8.9), and 0.4mol/L of each 5 and 3 primer.
The following primers were used: sense sgk (5-GCTTCC
TGGAACCACGGGCTCGTTTCTATG-3); antisense
sgk (5-CAGCATCTCATACAAGACAGCTCCCAG
GC-3); sense p21/waf1 (5-ACAGCAGAGGAAGAC
CATGTGGACCTGTC-3); antisense p21/waf1 (5-CTT
CCTCTTGGAGATCAGCCGGCGTTTG-3); sense
gadd45 (5-GAGAGCAGAAGACCGAAAGGATGG
ATAAGG-3); antisense gadd45 (5-CTGACGCGC
AGGATGTTGATGTCGTTCTC-3); sense gadd153
(5 -GGAAGCCTGGTATGAGGACCTGCAA
GAG-3); antisense gadd153 (5-CTTTCTCCTTCATG
CGCTGCTTTCCAGCC-3); sense ppara (5-GTGTG
AAGGCTGCAAGGGCTTCTTTCGGCG-3); anti-
sense ppara (5-TCCTGAGAGGATGACCCGGGC
TTTGACC-3); sense pura (5 -GCTCTGGCCAA
GCTCATCGACGACTACGG-3); antisense pura
(5-TCCTGCTGCTGCTGTTGCTGCTGGTGAAG-3);
sense G3PDH (5-ACCACAGTCCATGCCATCAC-3);
antisense G3PDH (5-TCCACCACCCTGTTGCTG
TA-3); sense tgf-b2 (5-GTCCAACCGGCGGAAGA
AGCGTGC-3); antisense tgf-b2 (5-GGAAGCAGA
AGCTTCTGGCTTTAT-3); sense MR (5-CAGATG
ATCCAAGTCGTGAAGTGG-3); and antisense MR
(5-CTGATGATCTCCACCAGCATTG-3).
PCR was performed in a Master Gradient Thermal
Cycler (Eppendorf, Hamburg, Germany) with the lowest
possible number of PCR cycles to detect small changes
in gene expression. PCR products were quantified on a
2% Tris/borate/EDTA (TBE) agarose gel stained with
ethidium bromide, visualized using an imaging system.
The band intensities were normalized to gapdh. Prior to
T/A cloning into pCR2.1 (Invitrogen Corporation, USA),
PCR fragments were extracted from agarose gel using
Qiaex (Qiagen). A BLAST search was performed for the
sequences of the cloned PCR fragments (http://www.
ncbi.nlm.nih.gov/BLAST) to confirm the identity of the
corresponding gene.
Data evaluation and statistics
Unless otherwise stated, mRNA quantification data
were obtained from at least three samples that were
stimulated separately. RT-PCR and Northern blotting
results are reported as mean values with standard devia-
tion calculated from three independent experiments.
SDS-polyacrylamide gel electrophoresis (PAGE) and
Western blotting
Cells (80% confluency) were treated with vehicle (0.01%
ethanol), aldosterone, aldosterone in the presence of spiro-
nolactone (10mol/L), or spironolactone alone for 2 hours
in 75 cm2 flasks. Cells were washed twice with PBS buffer
(Life Technologies) and stored at80C until harvested.
Cells were scraped with a cell scraper in 1 mL PIC
buffer [50 mmol/L Tris, pH 7.4, 2 mmol/L ethylenedi-
aminetetraacetic acid (EDTA), 2 mmol/L ethyleneglycol-
tetraacetate (EGTA), 1 tablet complete] (Roche Diagnos-
tics, Mannheim, Germany), dounce-homogenized, treated
with 10 L phenylmethylsulfonyl fluoride (PMSF) (100
mmol/L stock solution in ethanol) (Sigma), passed 10
times through a 27-gauge needle, and centrifuged at 9000g
for 10 minutes at 4C. The supernatant was removed and
stored at 20C. Aliquots of the whole cell lysate were
measured by Bio-Rad DC assay (Bio-Rad, Mu¨nchen, Ger-
many). Protein samples (50/100 g) were separated on
10 or 12% SDS-polyacrylamide gels and transferred to
nitrocellulose membranes (Schleicher and Schuell, Dassel,
Germany). The membrane was blocked overnight with
nonfat dry milk (Bio-Rad) and bovine serum albumin
(BSA) (Sigma) (3% each). For immunodetection, the
following antibodies were used: sheep polyclonal anti-
sgk (Upstate Biotechnology, Charlottesville, VA, USA),
mouse monoclonal anti-p21/waf1, mouse monoclonal
anti-gadd45, mouse monoclonal anti-gadd153 (all from
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Table 1. Differentially expressed transcripts in response to short-term aldosterone treatment in human renal epithelial (HRE) cells
Acc. Dot-signal
No. Gene/protein Function A1/A2
L24804 23 kD progesterone receptor-associated protein Hormone receptor 0.44
X17620 Nucleoside diphosphate kinase A (NDKA) Transcription activator 0.5
U07550 Mitochondrial 10-kD heat shock protein Heat shock protein 2.56
L06505 60 S ribosomal protein L12 Ribosomal protein 2.10
M65128 FK 506-binding protein 13 precursor Protein modification 2.71
M23419 Translation initiation factor 5  subunit Translation factor 2.20
U71216 Beta crystallin B3 Motility protein 2.49
M96684 Purine-rich single-stranded DNA-binding protein alpha (pura) Transcription activator/repressor 2.78
U09579 Cyclin-dependent-kinase inhibitor 1A wild-type p53 activated fragment 1 (p21/waf1) Transcription factor 2.66
M60974 Growth and damage inducible DNA 45 (gadd45) Stress response proteins/
transcription modulators 3.12
S40706 Growth and damage inducible DNA 153 (gadd153) 2.71
M74524 Ubiquitin-conjugating enzyme E2 17 kD Protein turnover 2.99
U90313 Glutathione s-transferase (GST) homolog Metabolism 2.78
Y00483 Glutathione peroxidase Metabolism 2.11
X79389 Glutathione s-transferase theta 1 (GST1) Xenobiotic transporter 2.91
L02932 Peroxisome proliferator activated receptor alpha (ppara) Nuclear receptor 2.23
cDNA was labeled and hybridized as described in the Methods section. Genes that were chosen for further analysis are shown in bold. Dot-signal A1/A2 indicates
the expression ratio of aldosterone treated cells vs. controls.
Santa Cruz Biotechnologies, Santa Cruz, CA, USA), and
mouse monoclonal anti-gapdh (Biodesign International,
Saco, ME, USA).
For detection, either antimouse horseradish peroxidase
or antigoat horseradish peroxidase (Dako, Hamburg,
Germany) were used at 1:2500 dilution together with the
Enhanced Chemiluminescence (ECL) Kit (Amersham
Pharmacia Biotech). Blots were stripped and subse-
quently reprobed with a human anti-G3PDH antibody
as a loading control. All results were subsequently nor-
malized to the respective GAPDH signal. Quantitative
results were obtained from densitometric analysis of films
corrected for background and are reported as mean and
standard deviation from three independent experiments.
RESULTS
Expression profiling of aldosterone-treated HRE cells
Of the more than 1400 genes examined, 14 genes were
found to be differentially expressed (up- or down-regu-
lated twofold or more) in response to aldosterone.
Among these up-regulated genes, five transcripts were
selected for their properties as modulators of transcrip-
tion for further analysis (shown in bold, Table 1).
Confirmation of differentially expressed genes by
RT-PCR and Northern-blotting
In order to corroborate microarray data, independent
methods such as semiquantitative RT-PCR and North-
ern blot analysis have been used. Early aldosterone–
up-regulated genes identified before were further ex-
amined by RT-PCR. In addition, we investigated the
mRNA expression of sgk, which was not represented on
cDNA expresssion arrays, in response to aldosterone.
Maximum mRNA expression of gadd45, gadd153, and
p21/waf1 was reached after 1 hour and, subsequently,
decreased close to control level (21⁄2 hours) and then
gradually rose again, thus exhibiting a biphasic behav-
ior, to a variable degree. In contrast, after an early peak
within 1 hour of aldosterone treatment, sgk expression
continuously declined, even below control level, after
16 hours (Fig. 1). All expression ratios were normalized
with respect to gapdh as a housekeeping gene.
In the early phase of aldosterone treatment, ppar
and pur mRNA expression was slightly elevated and
then gradually reached the maximum after 24 hours of
aldosterone treatment (2.3-fold), thus exhibiting a very
different induction pattern.
Northern blot analysis
Northern blots were performed to verify cDNA ex-
pression array and RT-PCR data. gapdh mRNA expres-
sion remained unchanged according to microarray analy-
sis. Therefore, gapdh was used to normalize RNA transfer.
Northern blot data were consistent with cDNA expression
data. Data from RT-PCR and Northern blotting show con-
gruent changes of mRNA expression over time (Fig. 2).
Detected transcripts appeared as single bands of the
following sizes: gadd45 1.3 kb, gadd153 1.6 kb, p21/
waf1 2.1 kb, pura 1.1 kb, ppara 1.8 kb and 2.3
kb for sgk. In the early phase of aldosterone treatment
(	2 hours), gadd45, gadd153, p21/waf1, and sgk were
significantly up-regulated (1.8- to 2.5-fold) (Fig. 2). In
the late phase of aldosterone treatment (4 hours),
mRNA expression of ppara and pura gradually increased
(2.2-fold and 2.4-fold, respectively) over time as well
(Fig. 2). To calculate the relative mRNA abundance, all
membranes were stripped and rehybridized with a probe
for gapdh.
Inhibitor studies
To investigate the effects of several inhibitors on the
mRNA expression of early genes in HRE cells, cells
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Fig. 1. Time course of induction for early (A)
and delayed (B) genes. Human renal epithelial
cells were incubated with 100 nmol/L aldoste-
rone or vehicle for the time indicated. Reverse
transcription-polymerase chain ractin (RT-
PCR) was done as described in the Methods
section. Signal intensities were normalized to
the GAPDH signal. Symbols for (A) are: (),
sgk; (), p21/waf1; (), gadd45; (), gadd
153). Symbols for (B) are: (), ppara; (),
pura; (), gapdh.
Fig. 2. Confirmation of reverse transcription-polymerase chain reac-
tion (RT-PCR) results by Northern blot analysis. Cells treated with
aldosterone or vehicle were harvested, total RNA and polyA RNA
was isolated, and Northern blot analysis of selected transcripts was
performed as described in the Methods section.
were treated with aldosterone alone or in combination
with various inhibitors. Actinomycin D (AcD) and cyclo-
heximide (CHX), which block mRNA transcription and
protein biosynthesis, respectively, as well as the gluco-
corticoid antagonist RU 486 and the mineralocorticoid
antagonist spironolactone, were used, with the steroidal
antagonists at 1000-fold excess over aldosterone. The
effects of aldosterone in the presence or absence of the
inhibitors on gadd45, gadd153, p21/waf1, and sgk mRNA
expression were tested by RT-PCR (Fig. 3). CHX alone
or in combination with aldosterone elevated the mRNA
level of all genes. While AcD reduced the mRNA level
of gadd45, gadd153, and sgk, the p21/waf1 mRNA level
was augmented. The MR inhibitor spironolactone low-
ered the mRNA-levels of gadd45, sgk, and p21/waf1.
mRNA expression of investigated genes could not be
blocked completely at the concentrations studied. The
induction of sgk and p21/waf1 mRNA by aldosterone
was decreased when GR was blocked by RU 486, indicat-
ing that their expression was mediated through both MR
and GR. Interestingly, mRNA expression of gadd153
was not affected by either inhibitor.
Western blot
To further validate and extend the results of the
mRNA analyses by cDNA arrays, RT-PCR and North-
ern blot analysis, we determined protein levels of sgk,
p21/waf1, gadd45, and gadd153 in HRE cells after 2
hours of aldosterone treatment to allow additional time
for protein synthesis.
Immunoblot experiments (Fig. 4) demonstrated a 2.5-
fold increase in sgk protein in response to aldosterone
compared to controls, while the addition of the inhibitor
spironolactone reduced the aldosterone effect to 1.6-
fold. Spironolactone alone had a marginal effect (mean
value 1.3-fold compared to control).
There was only a small effect on p21/waf1 on the
protein level (1.35-fold vs. control with aldosterone),
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Fig. 3. Inhibition studies of aldosterone up-
regulated transcripts. Human renal epithelial
cells were pre-incubated with 1 g/mL actino-
mycin D (A), 5 g/mL cycloheximide (B), 100
mol/L RU 486 (C), and 100 mol/L spirono-
lactone (D) for 5 minutes at 37C. Then aldo-
sterone or vehicle (control) were added and in-
cubation was continued for an additional 1 hour.
Cells were harvested, total RNA extracted,
and reverse transcription-polymerase chain re-
action (RT-PCR) performed using the primers
described before. Graphs show mean values
of three experiments and fold induction rela-
tive to control of indicated transcripts. Col-
umn 1, control; column 2, aldosterone; column
3, aldosterone and inhibitor; and column 4,
inhibitor only.
which could be blocked by spironolactone (1.06-fold).
Spironolactone alone had no detecable effect.
The amount of gadd45 protein was increased 1.44-fold
by aldosterone, while spironolactone again blocked the
response (1.1-fold vs. control). Spironolactone alone ap-
parently has a small effect, however, with questionable
significance.
A more prononunced effect of aldosterone was seen
with gadd153 (1.76-fold vs. control). This increase in
the amount of protein apparently was not blocked by
spironolactone (1.57-fold vs. control), while spironolac-
tone alone had no effect. In general, the results observed
at the protein level are in line with the data obtained
for mRNA induction.
The antibodies used here recognized bands with the
following molecular weights: sgk, 50 kD (specific) and
additional bands at 70 kD and 120 kD; p21/waf1, 20 kD
(single band); gadd45, 18 kD (specific) and an additional
band at 70 kD; and gadd153, 27 kD (single band).
DISCUSSION
Several experimental models are consistent with the
concept that aldosterone mediates renal injury. In animal
models, exogenous administration of mineralocorticoids
induced lesions of malignant nephrosclerosis and stroke
[13]. The development of this type of lesion is probably
due to the straight action of mineralocorticoids, since rats
show low plasma renin activity and respond poorly to
angiotensin-converting enzyme (ACE) inhibitor therapy.
Several lines of experimental evidence confirm that aldo-
sterone antagonists, independent of renin-angiotensin
blockade, have beneficial effects on the progression on
renal dysfunction associated with proteinuria and neph-
rosclerosis and on the progression of cardiac fibrosis.
The aim of this study was to investigate the effects of
aldosterone on HRE as an ex vivo model system and to
generate a gene expression profile to identify genes that
may participate in the development of renal dysfunction.
The cells used here are a mixed population comprising
epithelial cells from proximal and distal tubuli as well
as glomeruli. This mixed culture was chosen as, under
physiologic conditions, several cell types interact with
each other and may influence properties and reactivity
by paracrine phenomena. Among the genes regulated
by aldosterone that were identified in the first round of
screening, transcripts were chosen that were (1) strongly
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Fig. 4. Western blot analysis of sgk, p21/waf1, gadd45, and gadd153.
Fifty micrograms whole cell lysates from aldosterone (100 nmol/L, 2
hours) aldosterone-treated (left lanes) or control (right lanes) human
renal epithelial cells were separated by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE). Western blot analysis was
done as described in the Methods section. Upper group, images from
representative examples of Western blots. Abbreviations are: C, control;
A, aldosterone; A  I, aldosterone and spironolactone (10 mol/L); I,
spironolactone alone (10 mol/L). Lower group, graphic representation
of the protein levels detected. Each experiment series was normalized
with respect to control (control 
 100). Mean values and standard
deviations are shown.
regulated (factor 2 or more) and (2) have been reported
to modulate transcription or cell growth, as many patho-
logic phenomena linked to aldosterone involve abnormal
cell proliferation. Further studies on the time course
of induction of these transcripts revealed two different
patterns of response. Early aldosterone-regulated gene
products like sgk peaked within 1 to 2 hours of hormone
treatment, whereas ppara and pura reached maximum
induction at a later point (3 hours), similar to the classic
aldosterone-induced genes Na,K-ATPase and ENaCs
[14–18]. There is evidence that sgk may not only in modu-
late ENaCs and Na,K-ATPase, but is also involved in
fibrosing [19].
Aldosterone treatment also leads to a rapid induction
of two growth arrest and DNA damage-inducible pro-
teins (gadd45/153). Gadd proteins, normally induced by
cellular stress, play a critical role in the pathogenesis of
cardiovascular disease [20]. Similarly, we observed the
up-regulation of p21/waf1, a protein that is involved in
growth regulation. There is evidence that p21/waf1 plays
a central role in the development of fibrosis [21, 22].
The induction of p21/waf1 by aldosterone was transient,
returning near control level after 4 hours incubation with
aldosterone.
The other central aim of this study was the elucidation
of pathways for gene induction by aldosterone. At the
concentration used in this study (100 nmol/L), aldoste-
rone may act not only via MR but also may occupy a
significant fraction of GR, thus also inducing GR-medi-
ated transcription. This was the rationale for using both
the GR inhibitor RU 486 and the MR inhibitor spirono-
lactone to block the respective receptors and study their
contribution to gene induction. Both inhibitors are not
absolutely specific, but are to known to be ligands at
other receptors as well. However, in the experimental
design used here, no significant effect, neither agonist nor
antagonist compared to control, was seen when inhibitor
was used alone, and the only readout was the difference
of aldosterone stimulation experiments in the presence
or absence of inhibitors.
While sgk and p21/waf1 induction was reduced by both
RU 486 and spironolactone indicating participation of
both GR and MR, gadd45 induction was blunted by
spironolactone, but not by RU 486, thus suggesting a MR
pathway. Perhaps most surprising, the induction of gadd153
by aldosterone cannot be blunted by either RU 486 or
spironolactone. This indicates a pathway different from
classic GR and MR receptors. Fawcett et al [23] reported
a cyclic adenosine monophosphate (cAMP) responsive
element/activating transcription factor (CRE/ATF) pro-
moter controlling gadd153 (also called CHOP) expres-
sion, thus suggesting up-regulation by the active tran-
scription factor cAMP-responsive element-binding protein
(CREB). The activation of CREB involves phosphoryla-
tion by protein kinase A, which, in turn, is activated by
cAMP. In our laboratory, aldosterone has been shown
to increase intracellular cAMP levels in many cell types,
and CREB phosphorylation has been demonstrated in
vascular smooth muscle cells [4, 24], occurring within 10
minutes. Combining these findings, a possible mecha-
nism for the induction of gadd153 by aldosterone is sum-
marized in a scheme (Fig. 5). Although gadd153 is often
regarded to be a mere apoptosis marker, it, in fact, is a true
transcription factor that has been demonstrated to be
involved in erythroid differentiation and colony growth
[25], among others. Gadd153 can be phosphorylated by
p38 mitogen-activated protein kinase (MAPK), which is
part of the cellular stress response, and subsequently in-
duces transcription of a series of genes generally referred
to as DOC (downstream of CHOP) [26], which comprise
some proteins interacting with cytoskeletal structural pro-
teins (actin) and are thought to mediate changes in cell
phenotype in response to stress. This model is in line with
earlier studies that demonstrated the influence of second
messengers on genomic steroid action [27, 28].
For sgk, gadd45, and gadd153, up-regulation was com-
pletely blocked by AcD, but not by CHX. CHX alone
increased sgk, gadd45, p21/waf1, and gadd153 RNA, a
phenomenon observed for a wide variety of immediate
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Fig. 5. Model for the nonclassic induction of gadd153 by aldosterone.
Schematic presentation of early aldosterone action in human renal
epithelial (HRE) cells. Aldosterone acts via the classic genomic pathway
involving glucocorticoid receptor (GR) and mineralocorticoid receptor
(MR), inducing gadd45, p21/waf1, and sgk protein expression. An alter-
native, nongenomic pathway involving cyclic adenosine monophosphate
(cAMP) generation, protein kinase A (PKA) activation, and cyclic adeno-
sine monophosphate (cAMP)-responsive element-binding (CREB) phos-
phorylation is thought to induce gadd153/CHOP transcription, which,
in turn, may induce other genes if phosphorylated. Abbreviations are:
DOC, downstream of CHOP; MAPK, mitogen-activated protein kinase.
early genes, probably involving enhanced mRNA stabil-
ity. Surprisingly, p21/waf1 mRNA levels were augmented
by aldosterone even in the presence of either CHX or
AcD, suggesting a transcription independent mechanism
possibly involving the suppression of a short-lived RNase
[29]. Considering that p21/waf1 contains adenosine/uri-
dine-rich elements known to interfere with mRNA desta-
bilization [29, 30], such a transcription-independent ef-
fect could be mediated by MR and/or GR, which interact
directly or indirectly with the AU-rich element–specific
RNase. Liu et al [30] and Peppel, Vinci, and Baglioni
[29] found various hormones, including glucocorticoids,
to be involved in the control of mRNA half-life.
Apart from the confirmation of sgk being an immedi-
ate early gene strongly up-regulated in response to aldo-
sterone, additional early aldosterone up-regulated genes
have been identified, which participate in aldosterone
signaling. Examining the contribution of these genes to
the effects of aldosterone on renal and cardiac disease
is a promising field for future investigations. Our study
also provides a molecular insight into the early and late
phases of aldosterone-mediated action. The fact that up-
regulation of at least one transcript (gadd153) by aldoste-
rone is not inhibited by MR and GR antagonists supports
the hypothesis that some proteins are regulated via non-
classic mechanisms which may also be involved in the
progression of renal and cardiac disease. This is, to our
knowledge, the first direct piece of evidence for nonclas-
sic action of aldosterone on gene expression and may
give a mechanistic explanation for the inefficacy of classic
MR antagonists in the treatment of some aspects of renal
and other diseases involving aldosterone.
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